Anavex Life Sciences Corp.
AVXL
$9.53
-$0.02-0.21%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.50M | 2.62M | 3.15M | 2.91M | 2.79M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 14.33M | 12.42M | 13.18M | 13.64M | 14.08M |
Operating Income | -14.33M | -12.42M | -13.18M | -13.64M | -14.08M |
Income Before Tax | -13.24M | -11.20M | -12.11M | -11.74M | -12.21M |
Income Tax Expenses | -- | -- | -- | -124.00K | -- |
Earnings from Continuing Operations | -13.24M | -11.20M | -12.11M | -11.62M | -12.21M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -13.24M | -11.20M | -12.11M | -11.62M | -12.21M |
EBIT | -14.33M | -12.42M | -13.18M | -13.64M | -14.08M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.16 | -0.13 | -0.14 | -0.14 | -0.14 |
Normalized Basic EPS | -0.10 | -0.08 | -0.09 | -0.09 | -0.09 |
EPS Diluted | -0.16 | -0.13 | -0.14 | -0.14 | -0.14 |
Normalized Diluted EPS | -0.10 | -0.08 | -0.09 | -0.09 | -0.09 |
Average Basic Shares Outstanding | 85.38M | 85.07M | 84.81M | 84.80M | 84.54M |
Average Diluted Shares Outstanding | 85.38M | 85.07M | 84.81M | 84.80M | 84.54M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |